Abstract
Phosphoinositide 3-kinases (PI3Ks) control key signaling pathways in cancer cells, leading to cell proliferation, survival, motility and angiogenesis. In several human cancers, activation of PI3Ks results from gain-of-function or over-expression of PI3Ks and/or hyperactivity of up- or downstream players in the pathway. As inhibition of PI3Ks and downstream targets such as mammalian target of rapamycin (mTOR) has been shown to reduce tumor growth in vitro and in preclinical models, several small molecule inhibitors of PI3Ks are currently undergoing clinical trial as novel agents in cancer therapy. These drugs include inhibitors targeting all class I PI3Ks (α, β, γ, δ isoforms), compounds blocking selective PI3K isoforms and dual inhibitors active on both PI3Ks and mTOR. Herein, we summarize the pharmacology and preliminary clinical data of the main PI3K inhibitors undergoing clinical trial. We will also review the preclinical studies documenting the major effects of systemic PI3K inhibition on non-cancer tissues, which have shed light on potential side effects, caveats and limitations for PI3K blockade in patients.
Keywords: PI3K, mTOR, Akt, cancer, enzyme inhibitors, Phosphoinositide, proliferation, survival, motility, angiogenesis
Current Medicinal Chemistry
Title: Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations
Volume: 18 Issue: 18
Author(s): E. Ciraolo, F. Morello and E. Hirsch
Affiliation:
Keywords: PI3K, mTOR, Akt, cancer, enzyme inhibitors, Phosphoinositide, proliferation, survival, motility, angiogenesis
Abstract: Phosphoinositide 3-kinases (PI3Ks) control key signaling pathways in cancer cells, leading to cell proliferation, survival, motility and angiogenesis. In several human cancers, activation of PI3Ks results from gain-of-function or over-expression of PI3Ks and/or hyperactivity of up- or downstream players in the pathway. As inhibition of PI3Ks and downstream targets such as mammalian target of rapamycin (mTOR) has been shown to reduce tumor growth in vitro and in preclinical models, several small molecule inhibitors of PI3Ks are currently undergoing clinical trial as novel agents in cancer therapy. These drugs include inhibitors targeting all class I PI3Ks (α, β, γ, δ isoforms), compounds blocking selective PI3K isoforms and dual inhibitors active on both PI3Ks and mTOR. Herein, we summarize the pharmacology and preliminary clinical data of the main PI3K inhibitors undergoing clinical trial. We will also review the preclinical studies documenting the major effects of systemic PI3K inhibition on non-cancer tissues, which have shed light on potential side effects, caveats and limitations for PI3K blockade in patients.
Export Options
About this article
Cite this article as:
Ciraolo E., Morello F. and Hirsch E., Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations, Current Medicinal Chemistry 2011; 18 (18) . https://dx.doi.org/10.2174/092986711796011193
DOI https://dx.doi.org/10.2174/092986711796011193 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clostridium Difficile Infection Following Chemotherapy
Recent Patents on Anti-Infective Drug Discovery Circulating Nucleic Acids in Plasma and Serum: Roles in Diagnosis and Prognosis in Diabetes and Cancer
Infectious Disorders - Drug Targets Revision of QSAR, Docking, and Molecular Modeling Studies of Anti-Influenza Virus A (H1N1) Drugs and Targets: Analysis of Hemagglutinins 3D Structure
Current Computer-Aided Drug Design Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Fundamental, Electron Transfer Mechanism by Pyrylium-Type Ions for the Anticancer Drugs 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) and Flavone-8-Acetic Acid (FAA)
Current Medicinal Chemistry - Anti-Cancer Agents The Emerging Roles of the HERC Ubiquitin Ligases in Cancer
Current Pharmaceutical Design Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition Patent Review of Novel Nanostructrued Devices, Nanofabrication Methods and Applications in Nanofluidics and Nanomedicine
Recent Patents on Nanotechnology Apicidin Inhibited Proliferation and Invasion and Induced Apoptosis via Mitochondrial Pathway in Non-small Cell Lung Cancer GLC-82 Cells
Anti-Cancer Agents in Medicinal Chemistry Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) A Novel Cobalt(II) Coordination Complex Constructed from H<sub>2</sub>Pyri and 4,4′-Bipy: Synthesis, Characterization and Bioactivity
Anti-Cancer Agents in Medicinal Chemistry Ribonucleotide Reductase Inhibitors and Future Drug Design
Current Cancer Drug Targets Convection-Enhanced Delivery: Neurosurgical Issues
Current Drug Targets Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design Design of Combretastatin A-4 Analogs as Tubulin Targeted Vascular Disrupting Agent with Special Emphasis on Their Cis-Restricted Isomers
Current Pharmaceutical Design Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Multiple Roles of Transient Receptor Potential (TRP) Channels in Inflammatory Conditions and Current Status of Drug Development
Current Topics in Medicinal Chemistry Bioanalytical and Biophysical Techniques for the Elucidation of the Mode of Action of Metal-Based Drugs
Current Topics in Medicinal Chemistry Application of Three-dimensional (3D) Tumor Cell Culture Systems and Mechanism of Drug Resistance
Current Pharmaceutical Design Molecular Pathology of Pancreatic Cancer: From Bench-to-Bedside Translation
Current Drug Targets